BioClin Therapeutics said yesterday that it closed a $30 million Series B round led by new investors Sofinnova Ventures and Ysios Capital. Existing investors HealthCap, Life Sciences Partners and Tekla Capital Management also invested. The company plans to use the newly-acquired funds to advance its lead candidate, B-701, as a treatment for metastatic bladder cancer in […]